Best Exosome / Extracellular Vesicle CDMOs in China
· updated as new inspection, certificate, and trial data enters the platform
1
CDMOs tracked
1
Fully scored
Exosome and extracellular vesicle (EV) CDMOs manufacture next-generation delivery vehicles for RNA, proteins, and small molecules. As an emerging modality, the field is still standardizing cell-source, isolation, and potency methods.
Choosing an exosome CDMO turns on cell-source and culture scale, isolation method (TFF, chromatography), characterization, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
Last updated 2026-08-31. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
CoJourney Inc.
Horsham, PA (US HQ); Hangzhou, China (primary GMP manufacturing)
|
60.0 | — | — | Limited | 0 programs |
What to evaluate in a Exosome / Extracellular Vesicle CDMO
Cell source & scale
Confirm the producer cell source and whether culture is suspension-adapted for the volumes EV yields demand.
Isolation & purification
Isolation method (tangential-flow filtration, chromatography) drives yield, purity, and scalability. Ask how it performs at your target scale.
Characterization & potency
EV characterization (particle count, size, cargo, identity) and potency assays are still maturing — look for established, qualified methods.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
How do the BioSecure Act and 1260H list affect Chinese CDMO selection for US programs?
US sponsors evaluating Chinese CDMOs currently face two active US regulatory considerations. The DoD 1260H list designates named Chinese companies as "Chinese Military Companies" — WuXi AppTec was added in June 2026. Listing itself doesn't restrict commercial pharma work but affects federally-funded research access and creates procurement complications for sponsors with government contracts. The BioSecure Act is proposed federal legislation that would restrict federally-funded research and Medicare/Medicaid drug programs from working with named Chinese biotech companies (specifically BGI, MGI, Complete Genomics, WuXi AppTec, and WuXi Biologics as of current drafts). The bill has not passed as of 2026-08 but has bipartisan support. CDMO Signal does not encode US political risk into the Signal Score — the composite reflects regulatory quality, operations, financial stability, and capacity. Sponsors evaluating a Chinese CDMO for US-supplying programs should evaluate US regulatory risk separately as a distinct decision layer.
Chinese CDMOs with FDA and EMA inspection posture
Chinese CDMOs supplying US and European markets need active FDA and EMA GMP certifications on the specific facility. The FDA and EMA both conduct facility inspections in China, and Chinese CDMOs' inspection outcomes have generally improved over the past decade. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly. Chinese CDMOs with cross-jurisdictional certification rank higher on this pillar than domestic-market-only competitors. Cross-check with the US region ranking — Chinese CDMOs appearing on both rankings have demonstrated cross-jurisdictional inspection posture, which materially reduces regulatory risk for programs supplying US markets.
Which modality classes have the strongest Chinese CDMO capability?
China's CDMO capability is strongest in biologics (both mAb and biosimilar), viral vectors (particularly AAV, with substantial commercial-scale capacity via WuXi Advanced Therapies and others), and mRNA (rapid post-COVID capacity build). Small molecule and API manufacturing capacity is also substantial but sits outside CDMO Signal's primary coverage focus. Cross-reference with modality pages to filter Chinese CDMOs by capability: biologics, AAV, mRNA, or the viral vector umbrella. Individual profile pages surface facility-level detail.
Exosome / Extracellular Vesicle CDMOs — Frequently Asked Questions
Who are the top Exosome / Extracellular Vesicle CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Exosome / Extracellular Vesicle CDMOs include CoJourney Inc.. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
What should I look for in an exosome CDMO?
Confirm cell source and scalable culture, a robust isolation method (TFF or chromatography), qualified characterization and potency analytics, and a clean FDA and EMA/MHRA record.
Is exosome manufacturing standardized?
Not yet fully — cell-source, isolation, and potency methods are still maturing across the field, so a CDMO's specific platform and analytics maturity matter more than in established modalities.
Related modalities